Duke University Health System Launches OneDukeGen
In a new precision medicine study, genomic and health data will be collected to understand connections between genetics, health, and disease.
The Duke University Health System and School of Medicine, in partnership with nference, an AI-enabled software platform provider, are launching OneDukeGen. The aim of this precision medicine study is to advance healthcare by integrating comprehensive genomic data and health information toward understanding hereditary disease susceptibilities.
Led by principal investigator Svati Shah, MD, MHS, Associate Dean of Genomics, the study hopes to recruit over 100,000 consented Duke patients. The study is designed to ensure a diverse representation of populations, and was informed through input from community groups. The study will also offer return of genetic sequencing results from the research.
The collaborators stated in a release that Duke researchers and clinicians who will work in tandem to integrate research findings into patient care, and hopes to bridge the gap between scientific discovery and clinical practice.
Learn more about the OneDukeGen study and how Duke patients will be invited to participate.
Reference: “Duke University Health System Launches OneDukeGen, a New Precision Medicine Study,” August 15, 2023. Duke University School of Medicine.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
